“Insulins are typically heavily rebated products, and Part D beneficiaries’ out-of-pocket costs are based on a pre-rebated list price,” ADVI VP Lindsay Bealor Greenleaf explained to BioWorld about the costs of insulin
“Insulins are typically heavily rebated products, and Part D beneficiaries' out-of-pocket costs are based on a pre-rebated list price"
[el-text]
Written by Mari Serebrov
***excerpt***
“Insulins are typically heavily rebated products, and Part D beneficiaries’ out-of-pocket costs are based on a pre-rebated list price”
***end excerpt***
[/el-text]
View full article here
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.